![]() |
|
|
Vol. 300, Issue 1, 188-194, January 2002
New York Medical College, Department of Pharmacology, Valhalla, New York (A.H., M.L.S., A.N., N.G.A.); Jagiellonian University, Medical College, Department of Pharmacology, Cracow, Poland (R.O., R.G.); Robert Wood Johnson Medical School, New Brunswick, New Jersey (E.L.); and The Rockefeller University, New York, New York (A.K.)
| |
Abstract |
|---|
|
|
|---|
Heme oxygenase (HO) is a microsomal enzyme that oxidatively cleaves
heme to form biliverdin, with the release of iron and carbon monoxide
(CO). HO not only controls the availability of heme for the synthesis
of heme proteins but also is responsible for the generation of CO,
which binds to the heme moiety of heme proteins thus affecting their
enzymatic activity. Cyclooxygenase (COX) is a heme protein that
catalyzes the conversion of arachidonic acid to prostaglandin
H2, the precursor of prostanoids that participate in the
regulation of vascular function. The goal of the present study was to
determine whether the heme-HO system regulates COX enzyme expression
and activity in vascular endothelial cells. Endothelial cells stably
transfected with the human HO-1 gene exhibited a severalfold increase
in human HO-1 mRNA levels, which was accompanied by an increase in HO
activity and a marked decrease in prostaglandin (PG) E2 and
6-keto-PGF1
levels. Exposure of cells to
CoCl2, an inducer of HO-1 gene expression, resulted in
increases in HO-1 protein levels and HO activity. The increase in HO
activity was associated with a subsequent decrease in COX activity,
which returned to normal levels following normalization of HO activity.
The addition of heme resulted in an increase in COX activity with an
increase in PGE2 and 6-keto-PGF1
levels. The
degree of HO-1 expression and, consequently, the level of cellular
heme, were directly related to COX activity. These results demonstrate
that the heme-HO system can function as a cellular regulator of the
expression of vascular COX, thus influencing the generation of
prostanoids, PGE2 and PGI2, known to play a role in vascular homeostasis.
| |
Introduction |
|---|
|
|
|---|
Cyclooxygenase(s)
catalyzes the oxygenation and peroxidation of arachidonic acid to
prostaglandin endoperoxide H2, the immediate precursor of prostaglandins and thromboxane. Two COX isoforms encoded
by two related genes have been identified; COX-1 is constitutively expressed and is considered to generate prostaglandins for normal physiological functions whereas COX-2 is, in most tissues, an inducible
enzyme expressing rapidly and transiently in response to a variety of
stimuli (Smith et al., 1996
). Both COX isoforms are heme proteins (van
der Ouderaa et al., 1979
). Heme binds to the COX apoenzyme with a
stoichiometry of approximately one heme molecule per each subunit
(Smith and Marnett, 1991
). It is well documented that the heme
prosthetic group of COX is essential for the expression of catalytic
activity (Smith and Marnett, 1991
). Accordingly, the possibility arises
that variations in the cellular levels of heme impact on the amount of
catalytically active COX present in cells.
The cellular level of heme is regulated by the rate of its synthesis
and degradation. Heme degradation occurs almost exclusively by
oxidative cleavage of the
-meso carbon bridge of heme, eventually leading to the formation of equimolar amounts of biliverdin, iron, and
CO. The heme oxygenase (HO) system controls the rate-limiting step in
heme degradation. To date, three HO isoforms (HO-1, HO-2, and HO-3)
encoded by different genes have been identified (McCoubrey et al.,
1992
, 1997
; Shibahara et al., 1993
). HO-1 is a 32-kDa heat shock
protein (Shibahara et al., 1987
; Mitani et al., 1989
), which is
inducible by numerous stimuli (Abraham et al., 1996
). HO-2 is a
constitutively synthesized 36-kDa protein, which is abundant in the
brain and testis (McCoubrey et al., 1992
; Maines, 1997
). HO-3 is
related to HO-2 but is the product of a different gene, and its ability
to catalyze heme degradation is much lower than HO-1 (McCoubrey et al.,
1997
).
The goal of the present study was to determine whether interventions
that alter cellular heme levels influence COX enzyme expression and
activity. Previously we established a model of rabbit coronary
microvessel endothelial cells (RCME cells) overexpressing the human
HO-1 gene (Abraham et al., 1995
). We used these cells, as well as
endothelial cells in which HO activity was modulated by chemical
inducers, and measured the expression of COX isoforms and the
generation of COX-derived prostaglandins (PG). The results demonstrate
that the heme-HO system may function as a cellular regulator of the
expression of vascular COX, thus influencing the generation of
prostanoids, PGE2 and PGI2,
known to play a role in vascular homeostasis.
| |
Materials and Methods |
|---|
|
|
|---|
Vascular Endothelial Cell Cultures.
RCME cells were isolated
from the mid-portion of the rabbit myocardium by collagenase digestion,
filtration, and centrifugation as described by Gerritsen et al. (1988)
.
The cells were seeded onto fibronectin-coated six-well culture plates
and incubated in Dulbecco's modified Eagle's medium containing
20% plasma-derived serum, endothelial cell growth factor at 100 µg/ml, and 2 mM L-glutamine at 37°C. After 2 h in
a standard humidified incubator, nonadherent cells were removed.
Endothelial cell colonies appeared in 2 to 5 days and were initially
characterized by their morphology (i.e., closely apposed cells with a
polygonal morphology). Cultures free of pericytes and smooth muscle
cells were subcultured. Homogeneity of endothelial cell cultures was
assessed by acetylated low-density lipoprotein labeling followed
by visual fluorescence microscopy and fluorescence-activated cell
sorting. Cells used in the experiments (passages 12-25) were cultured
in Dulbecco's modified Eagle's medium and 10% fetal calf serum
supplemented with 20 mM Hepes, 0.35 mg/ml L-glutamine, and
0.06 mg/ml gentamicin. These cells were used to overexpress the human
HO-1 gene by transfection and clonal selection (Abraham et al., 1995
).
Cells overexpressing the human HO-1 gene, referred to as RCME-HHO-1
cells, were grown in parallel with control RCME cells as previously
described (Abraham et al., 1995
).
Northern Analysis.
Total RNA was isolated either by the
guanidinium thiocyanate-phenol extraction method or using TRIzol
reagent (Invitrogen) following the instructions provided by the
manufacturer. Total RNA (10 µg per lane) was denatured,
electrophoresed on 1.2% agarose formaldehyde gels, transferred to a
positively charged nylon membrane (Hybond N+;
Amersham Pharmacia Biotech, Piscataway, NJ) and UV cross-linked (Stratalinker; Stratagene, La Jolla, CA). Membranes were prehybridized for 1 to 2 h at 60°C and subsequently hybridized overnight at 60°C with random primer [32P]dCTP-labeled
human HO-1 cDNA, rat HO-1 cDNA, or
glyceraldehyde-3-phosphate dehydrogenase (GAPDH) cDNA
(CLONTECH, Palo Alto, CA). The blots were washed three times with a
solution containing 0.5% bovine serum albumin, 5% SDS, and 1 mM EDTA
in 0.2 × standard saline citrate at 56 to 60°C and then exposed
to X-ray film at
80°C.
Immunoblot Analysis. Cells were incubated with stimulants in T75 flasks for 24 h; they were then washed with phosphate-buffered saline and trypsinized [0.05% trypsin (w/v) with 0.02% EDTA]. The pellets were lysed in buffer [50 mM Tris-Cl, 10 mM EDTA, 1% Triton X-100 (v/v), 1% PMSF, 0.05 mM pepstatin A, and 0.2 mM leupeptin] and after mixing with sample loading buffer [50 mM Tris-Cl, 10% SDS (w/v), 10% glycerol (v/v), 10% 2-mercaptoethanol (v/v), and 0.04% bromphenol blue] in a ratio of 4:1 were boiled for 5 min. Samples (10 µg of protein) were loaded onto 12% gels and subjected to electrophoresis (150 V, 80 min). The separated proteins were transferred to nitrocellulose membranes (1 h, 200 mA per gel; Bio-Rad, Hercules, CA). After transfer, the blots were incubated overnight with 5% nonfat milk in TTBS followed by incubation with 1:1000 dilution of the primary antibody for 3 h. The polyclonal rabbit antibodies, directed against the human HO-1, rat HO-1, or rat HO-2, were from Stressgen Biotechnologies Corp. (Victoria, BC, Canada). The polyclonal rabbit antibody directed against the mouse COX-2 and goat antibody against human COX-1 were from Cayman Chemical (Ann Arbor, MI). After washing with TTBS, the blots were incubated for 2 h with secondary antibody (1:5000) conjugated with alkaline phosphatase. Finally, the blots were developed using a premixed solution containing 0.56 mM 5-bromo-4-chloro-3-indolyl phosphate and 0.48 mM nitroblue tetrazolium in buffer (10 mM Tris-HCl, 100 mM NaCl, 59.3 µM MgCl2, pH 9.5). The blots were scanned, and the optical density of the bands was measured using Scion Image software (Scion Corp., New York, NY).
Heme Oxygenase Activity Assay.
HO activity was assayed in
homogenates of endothelial cells as previously described (Chernick et
al., 1989
). Cell homogenates were incubated with 50 µM heme, 2 mg/ml
rat liver cytosol (as a source of biliverdin reductase), 1 mM
MgCl2, 3 units of glucose-6-phosphatase dehydrogenase, 1 mM glucose 6-phosphate, and 2 mM
NADP+ in 0.5 ml of 0.1 M potassium phosphate
buffer, pH 7.4, for 30 min at 37°C. The reaction was terminated by
placing the tubes on ice and bilirubin was extracted with chloroform
(Chernick et al., 1989
). The amount of bilirubin generated was
determined using a dual beam scanning spectrophotometer (Lambda 17 UV-visible; PerkinElmer Instruments, Norwalk, CT) and is defined as the
difference between 464 and 530 nm (extinction coefficient: 40 mM
1 cm
1 for bilirubin).
Results were expressed as nanomoles of bilirubin/milligram of
protein/hour.
Cellular Heme Content.
Endothelial cells were washed twice
with cold 0.15 M KCl and harvested by scraping the flashes with a
rubber policeman. Cells were harvested in an Eppendorf tube, and heme
content was measured by the pyridine hemochromogen method (Fuhrhop and
Smith, 1975
). Briefly, cells were resuspended in 0.9% NaCl and mixed
with a solution of 25% (v/v) pyridine in 0.075 M NaOH, and the heme
content was measured by using the reduced solution minus the oxidized difference spectrum between 390 and 600 nm. The absorbance peak corresponding to the heme band at 418 and 575 nm was determined using
an absorption coefficient of 32 mM
1
cm
1 (Fuhrhop and Smith, 1975
). Values were
expressed as nanomoles of heme/milligram of cell homogenate protein.
Measurement of PGE2 and 6-Keto-PGF1
Levels in Culture Medium.
The levels of PGE2
and the stable metabolite of PGI2,
6-keto-PGF1
, were determined in the medium of
endothelial cell cultures using an enzyme-linked immunoassay (EIA).
Endothelial cells were counted and seeded in 24-well plates (1.2 × 104 cells/well). Cells were treated with
CoCl2 (150 µM), heme (10 µM), and Sn-mesoporphyrin
(SnMP;10 µM) for 24 h, after which the medium were removed and
stored at
80°C. Solid-phase enzyme immunoassay was performed using
enzyme-linked immunosorbent assay kits following instruction provided
by the manufacturer (Cayman Chemical).
Statistical Analysis. The data are presented as mean ± S.E. for the number of experiments. Statistical significance (p < 0.05) was determined by the Fisher method of multiple comparisons. For comparison between treatment groups, the null hypothesis was tested by single-factor analysis of variance for multiple groups or unpaired t test for two groups.
| |
Results |
|---|
|
|
|---|
Modulation of HO Activity in RCME and RCME-HHO-1 Cells.
As
seen in Fig. 1A, RCME cells treated with
CoCl2 (150 µM) or heme (10 µM) resulted in an
increase of HO-1 mRNA without a significant increase in HO-2 or GAPDH
mRNA. Similarly, RCME cells transfected with human HO-1 gene
(RCME-HHO1) expressed the human HO-1 mRNA, but there was no increase in
human HO-1 gene expression following treatment with
CoCl2 or heme due to the absence of promoter in
the transduced gene (Fig. 1B). However, rabbit HO-1 in cells transfected with the human HO-1 gene responded to the HO inducers, CoCl2 and heme, in a manner similar to that of
nontransfected cells (Fig. 1, B compared with A) without a significant
modulation of GAPDH (Fig. 1B) or HO-2 expression (data not shown).
|
|
|
Effect of HO Induction and Inhibition on Prostaglandin Levels in
RCME Cells.
Under control conditions, the levels of
PGE2 in the culture medium of RCME cells were
approximately 20 times higher than those of
6-keto-PGF1
in agreement with previous reports
of prostanoid synthesis in cultured endothelial cells derived from
microvessels (Gerritsen et al., 1988
). The addition of heme (10 µM)
to the culture medium increased the levels of
6-keto-PGF1
and PGE2 by
62 and 50%, respectively (Fig. 4), which
is indicative of enhanced prostaglandin synthesis. Interestingly, SnMP
(10 µM) did not significantly affect basal or heme-stimulated
prostaglandin levels in the culture medium. Hence,
PGE2 levels were 30,130 ± 2,152 and
33,241 ± 2,890 pg/ml in the culture medium of untreated cells and
cells treated with SnMP (n = 6, p = 0.50), respectively. Similarly, 6-keto-PGF1
levels in untreated cells and cells treated with SnMP were 1,645 ± 103 and 1,845 ± 103 pg/ml, respectively (n = 6, p = 0.20). Moreover, in the cells treated with heme
(n = 6) and heme + SnMP (n = 3), PGE2 levels were 44,620 ± 1,656 and
42,370 ± 2,627 pg/ml, respectively, whereas
6-keto-PGF1
levels amounted to 2,799 ± 402 and 2,222 ± 131 pg/ml in heme- and heme + SnMP-treated cells,
respectively.
|
and PGE2 in
the culture medium (Fig. 4). In another set of experiments, RCME cells were pretreated with CoCl2 for 24 h, after
which CoCl2 was withdrawn from the culture by
washing the cells with phosphate-buffered saline and adding fresh
medium for an additional 24 h. CoCl2
withdrawal resulted in a return to normal levels of HO activity,
PGE2, and 6-keto-PGF1
(data not shown).
Prostaglandin Levels and COX Expression in RCME Cells Expressing
Human HO-1.
The basal levels of
6-keto-PGF1
and PGE2 in
culture medium were decreased by 85% in cells expressing the human
HO-1 (RCME-HHO-1 cells) compared with untransduced RCME cells (Fig.
5). RCME cells transduced with the empty
expression vector expressed a level of PGE2 and
6-keto-PGF1
similar to that seen in
untransduced cells (data not shown). Additional experiments in
RCME-HHO-1 cells revealed that incubation of cells with heme increased
the levels of PGE2 by 2-fold (from 4016 ± 717 to 8264 ± 758 pg/ml; n = 3, p < 0.001). The increase in the levels of
6-keto-PGF1
in the culture medium of
RCME-HHO-1 following heme was not significant (353 ± 96 and
426 ± 15 pg/ml in untreated RCME-HHO-1 and cells treated with
heme, respectively).
|
|
Effect of Heme on Prostaglandin Levels and COX Expression in
Primary Cultures of Endothelial Cells.
High-passage cultured
endothelial cells may differ functionally from first-passage cultured
endothelial cells, which are less likely to dedifferentiate. Therefore,
additional experiments using primary cultures of BAEC were performed to
assess the effect of the heme-HO system on prostaglandin levels and COX
expression. As shown in Fig. 7A,
incubation of cells with heme for 24 h increased 6-keto-PGF1
and PGE2 by
2- and 4-fold, respectively (Fig. 7A). Western blot analysis showed
that incubation of primary cultures with heme resulted in up-regulation
of HO-1 with no significant effect on either HO-2, COX-1, or COX-2
protein levels (Fig. 7B). The lack of effect of heme on COX protein may
be due to the presence of heme levels in primary cells as compared with
cell lines.
|
| |
Discussion |
|---|
|
|
|---|
This study demonstrates, for the first time, that the heme-HO system of endothelial cells participates in the regulation of prostaglandin production by these cells, presumably by influencing the availability of heme for the manufacture of catalytically active COX. Two key findings substantiate this conclusion.
The first key finding is that the production of the COX products
PGE2 and 6-keto-PGF1
(the nonenzymatic derivative of PGI2) was greatly
diminished in RCME cells treated with CoCl2 or
transfected with the human HO-1 gene. In agreement with previous reports (Schwartzman et al., 1986
), treatment with
CoCl2 increased the expression of HO-1 in RCME
cells, enhancing HO activity and presumably decreasing cellular heme,
as shown elsewhere (Abraham et al., 1995
). Transfection of RCME cells
with the human HO-1 gene resulted in augmentation of HO-1 expression,
elevation of HO activity, and reduction of cellular heme levels. Hence,
the production of COX products by vascular endothelial cells appears to
be down-regulated in experimental settings in which HO-1 is overexpressed and cellular heme is reduced.
The second key finding is that treatment of cultured endothelial cells,
RCME or BAEC, with heme increases the production of PGE2 and 6-keto-PGF1
. In
agreement with previous reports, this intervention also caused
induction of HO-1 with attendant augmentation of HO activity in
endothelial cells (Abraham et al., 1995
). The activation of
heme-degrading mechanisms in endothelial cells exposed to exogenous
heme is regarded as a homeostatic response to augmentation of cellular
heme levels (Deramaudt et al., 1998
; Wagener et al., 1999
). In our
study, the stimulatory effect of heme on prostaglandin production by
RCME cells was not altered by concurrent treatment with the HO
inhibitor SnMP. Accordingly, up-regulation of prostaglandin production
in endothelial cells treated with heme may be ascribed to heme itself
rather than to a product of its metabolism by HO.
A priori, up-regulation of prostaglandin production by heme in
endothelial cells may result from an increase in the amount of
arachidonic acid that is available to COX as well as an increase in the
expression and/or activity of COX. There is no evidence, however, that
cellular heme influences either the rate of arachidonic acid acylation
or reacylation, the balance of which determines the amount of
arachidonic acid available for prostaglandin synthesis (Farooqui et
al., 2000
). On the other hand, it is known that heme bound to histidine
residues of the peroxidase binding site of COX isoforms is required for
catalytic activity (Smith and Marnett, 1991
). Therefore, it is likely
that the alterations in prostaglandin production observed in
endothelial cells subjected to interventions that increase or decrease
cellular heme are the result of directional alterations in the levels
of catalytically active COX.
According to our study, the expression of COX-1 protein in RCME cells transfected with the human HO-1 gene does not correlate well with the production of prostaglandins. We found that although human HO-1-expressing cells contain more COX-1 protein than nontransfected cells, they produce less prostaglandins. One interpretation of these observations is that COX-1 protein manufactured by endothelial cells expressing human HO-1, although up-regulated, is compromised in terms of catalytic activity because of a less than optimal heme availability. Another possibility is that prostaglandin production in RCME cells is driven primarily by COX-2, the expression of which is significantly down-regulated in cells transfected with the human HO-1. However, preliminary experiments using a selective COX-2 inhibitor (NS398) suggested that COX-2 is not the primary source for the generation of PGE2 and PGI2 in these cells.
The design of the current study did not permit examination of
additional mechanisms by which alterations in status of the heme-HO
system of endothelial cells impact on prostaglandin production. For
example, it is conceivable that reductions in cellular heme decrease
PGI2 synthase expression, since this enzyme, like
COX, is a heme protein (Tanabe and Ullrich, 1995
). Consideration also should be given to the possibility that CO formed during metabolism of
heme by HO influences the enzymatic activity of
PGI2 synthase (Tanabe and Ullrich, 1995
). Our
results demonstrating that, in RCME cells expressing human HO-1,
addition of heme greatly increased PGE2 levels
without affecting the levels of 6-keto-PGF1
support these assumptions.
In summary, the present study documents a regulatory action of the heme-HO system in endothelial cells on prostaglandin production. Up-regulation of HO-1 leading to reduction in cellular heme brings about a decrease of prostaglandin synthesis. We take this finding as indicative that variations in cellular heme levels impact prostaglandin production in endothelial cells by influencing the amount of catalytically active COX.
| |
Acknowledgments |
|---|
We thank Dr. Hatem El Sabaaway and Sylvia Botros for assistance in conducting the experiments.
| |
Footnotes |
|---|
Accepted for publication September 26, 2001.
Received for publication June 28, 2001.
R.O. and A.H. contributed equally to the development of this research paper. This work was supported in part by National Institutes of Health Grants HL34300, DK56601, and American Heart Grant 50948T.
Address correspondence to: Dr. Nader G. Abraham, Professor and Director of Gene Therapy, Department of Pharmacology, New York Medical College, Valhalla, NY, 10595. E-mail: nader_abraham{at}nymc.edu
| |
Abbreviations |
|---|
COX, cyclooxygenase; HO, heme oxygenase; RCME cells, rabbit coronary microvessel endothelial cells; PG, prostaglandin; BAEC, bovine aortic endothelial cells; GAPDH, glyceraldehyde-3-phosphate dehydrogenase; TTBS, Tween 20/Tris-buffered saline; EIA, enzyme-linked immunoassay; SnMP, Sn-mesoporphyrin; RCME-HHO-1, RCME transfected with the human HO-1 cDNA; HHO-1, human HO-1; NS398, N-(2-cyclohexyloxy-4-nitrophenyl)methanesulfonamide.
| |
References |
|---|
|
|
|---|
This article has been cited by other articles:
![]() |
F. T. Botros, M. C. Prieto-Carrasquero, V. L. Martin, and L. G. Navar Heme oxygenase induction attenuates afferent arteriolar autoregulatory responses Am J Physiol Renal Physiol, October 1, 2008; 295(4): F904 - F911. [Abstract] [Full Text] [PDF] |
||||
![]() |
K. Patil, L. Bellner, G. Cullaro, K. H. Gotlinger, M. W. Dunn, and M. L. Schwartzman Heme Oxygenase-1 Induction Attenuates Corneal Inflammation and Accelerates Wound Healing after Epithelial Injury Invest. Ophthalmol. Vis. Sci., August 1, 2008; 49(8): 3379 - 3386. [Abstract] [Full Text] [PDF] |
||||
![]() |
D. E. Stec, H. A. Drummond, and T. Vera Role of Carbon Monoxide in Blood Pressure Regulation Hypertension, March 1, 2008; 51(3): 597 - 604. [Full Text] [PDF] |
||||
![]() |
G. Kronke, A. Kadl, E. Ikonomu, S. Bluml, A. Furnkranz, I. J. Sarembock, V. N. Bochkov, M. Exner, B. R. Binder, and N. Leitinger Expression of Heme Oxygenase-1 in Human Vascular Cells Is Regulated by Peroxisome Proliferator-Activated Receptors Arterioscler. Thromb. Vasc. Biol., June 1, 2007; 27(6): 1276 - 1282. [Abstract] [Full Text] [PDF] |
||||
![]() |
S. Villanueva, C. Cespedes, A. A. Gonzalez, C. P. Vio, and V. Velarde Effect of ischemic acute renal damage on the expression of COX-2 and oxidative stress-related elements in rat kidney Am J Physiol Renal Physiol, May 1, 2007; 292(5): F1364 - F1371. [Abstract] [Full Text] [PDF] |
||||
![]() |
N. Li, F. Yi, E. A. dos Santos, D. K. Donley, and P.-L. Li Role of Renal Medullary Heme Oxygenase in the Regulation of Pressure Natriuresis and Arterial Blood Pressure Hypertension, January 1, 2007; 49(1): 148 - 154. [Abstract] [Full Text] [PDF] |
||||
![]() |
R. Stocker and M. A. Perrella Heme Oxygenase-1: A Novel Drug Target for Atherosclerotic Diseases? Circulation, November 14, 2006; 114(20): 2178 - 2189. [Full Text] [PDF] |
||||
![]() |
F. Seta, L. Bellner, R. Rezzani, R. F. Regan, M. W. Dunn, N. G. Abraham, K. Gronert, and M. Laniado-Schwartzman Heme Oxygenase-2 Is a Critical Determinant for Execution of an Acute Inflammatory and Reparative Response Am. J. Pathol., November 1, 2006; 169(5): 1612 - 1623. [Abstract] [Full Text] [PDF] |
||||
![]() |
E. Rydkina, A. Sahni, R. B. Baggs, D. J. Silverman, and S. K. Sahni Infection of Human Endothelial Cells with Spotted Fever Group Rickettsiae Stimulates Cyclooxygenase 2 Expression and Release of Vasoactive Prostaglandins Infect. Immun., September 1, 2006; 74(9): 5067 - 5074. [Abstract] [Full Text] [PDF] |
||||
![]() |
A. I. Goodman, P. N. Chander, R. Rezzani, M. L. Schwartzman, R. F. Regan, L. Rodella, S. Turkseven, E. A. Lianos, P. A. Dennery, and N. G. Abraham Heme Oxygenase-2 Deficiency Contributes to Diabetes-Mediated Increase in Superoxide Anion and Renal Dysfunction J. Am. Soc. Nephrol., April 1, 2006; 17(4): 1073 - 1081. [Abstract] [Full Text] [PDF] |
||||
![]() |
M. Ishikawa, M. Kajimura, T. Adachi, K. Maruyama, N. Makino, N. Goda, T. Yamaguchi, E. Sekizuka, and M. Suematsu Carbon Monoxide From Heme Oxygenase-2 Is a Tonic Regulator Against NO-Dependent Vasodilatation in the Adult Rat Cerebral Microcirculation Circ. Res., December 9, 2005; 97(12): e104 - e114. [Abstract] [Full Text] [PDF] |
||||
![]() |
M. Hill, V. Pereira, C. Chauveau, R. Zagani, S. Remy, L. Tesson, D. Mazal, L. Ubillos, R. Brion, K. Ashgar, et al. Heme oxygenase-1 inhibits rat and human breast cancer cell proliferation: mutual cross inhibition with indoleamine 2,3-dioxygenase FASEB J, December 1, 2005; 19(14): 1957 - 1968. [Abstract] [Full Text] [PDF] |
||||
![]() |
H. Zhou, F. Lu, C. Latham, D. S. Zander, and G. A. Visner Heme Oxygenase-1 Expression in Human Lungs with Cystic Fibrosis and Cytoprotective Effects against Pseudomonas Aeruginosa In Vitro Am. J. Respir. Crit. Care Med., September 15, 2004; 170(6): 633 - 640. [Abstract] [Full Text] [PDF] |
||||
![]() |
C. Taille, J. El-Benna, S. Lanone, M.-C. Dang, E. Ogier-Denis, M. Aubier, and J. Boczkowski Induction of Heme Oxygenase-1 Inhibits NAD(P)H Oxidase Activity by Down-regulating Cytochrome b558 Expression via the Reduction of Heme Availability J. Biol. Chem., July 2, 2004; 279(27): 28681 - 28688. [Abstract] [Full Text] [PDF] |
||||
![]() |
L. Yang, S. Quan, A. Nasjletti, M. Laniado-Schwartzman, and N. G. Abraham Heme Oxygenase-1 Gene Expression Modulates Angiotensin II-Induced Increase in Blood Pressure Hypertension, June 1, 2004; 43(6): 1221 - 1226. [Abstract] [Full Text] [PDF] |
||||
![]() |
A. M. Vicente, M. I. Guillen, A. Habib, and M. J. Alcaraz Beneficial Effects of Heme Oxygenase-1 Up-Regulation in the Development of Experimental Inflammation Induced by Zymosan J. Pharmacol. Exp. Ther., December 1, 2003; 307(3): 1030 - 1037. [Abstract] [Full Text] [PDF] |
||||
![]() |
N. Thengchaisri and L. Kuo Hydrogen peroxide induces endothelium-dependent and -independent coronary arteriolar dilation: role of cyclooxygenase and potassium channels Am J Physiol Heart Circ Physiol, December 1, 2003; 285(6): H2255 - H2263. [Abstract] [Full Text] [PDF] |
||||
![]() |
M. Demasi, L. G. Cleland, R. J. Cook-Johnson, G. E. Caughey, and M. J. James Effects of Hypoxia on Monocyte Inflammatory Mediator Production: DISSOCIATION BETWEEN CHANGES IN CYCLOOXYGENASE-2 EXPRESSION AND EICOSANOID SYNTHESIS J. Biol. Chem., October 3, 2003; 278(40): 38607 - 38616. [Abstract] [Full Text] [PDF] |
||||
![]() |
F. Rodriguez, R. Kemp, M. Balazy, and A. Nasjletti Effects of Exogenous Heme on Renal Function: Role of Heme Oxygenase and Cyclooxygenase Hypertension, October 1, 2003; 42(4): 680 - 684. [Abstract] [Full Text] [PDF] |
||||
![]() |
F. A. D. T. G. Wagener, H.-D. Volk, D. Willis, N. G. Abraham, M. P. Soares, G. J. Adema, and C. G. Figdor Different Faces of the Heme-Heme Oxygenase System in Inflammation Pharmacol. Rev., September 1, 2003; 55(3): 551 - 571. [Abstract] [Full Text] [PDF] |
||||
![]() |
F. Rodriguez, F. Zhang, S. Dinocca, and A. Nasjletti Nitric oxide synthesis influences the renal vascular response to heme oxygenase inhibition Am J Physiol Renal Physiol, June 1, 2003; 284(6): F1255 - F1262. [Abstract] [Full Text] [PDF] |
||||
![]() |
L. Malaguarnera, S. Quan, M. R. Pilastro, N. G. Abraham, and A. Kappas Diminished Heme Oxygenase Potentiates Cell Death: Pyrrolidinedithiocarbamate Mediates Oxidative Stress Experimental Biology and Medicine, May 1, 2003; 228(5): 459 - 465. [Abstract] [Full Text] [PDF] |
||||
![]() |
A. M. Vicente, M. I. Guillin, and M. J. Alcaraz Participation of Heme Oxygenase-1 in a Model of Acute Inflammation Experimental Biology and Medicine, May 1, 2003; 228(5): 514 - 516. [Abstract] [Full Text] [PDF] |
||||
![]() |
A. K. Kiemer, N. Bildner, N. C. Weber, and A. M. Vollmar Characterization of Heme Oxygenase 1 (Heat Shock Protein 32) Induction by Atrial Natriuretic Peptide in Human Endothelial Cells Endocrinology, March 1, 2003; 144(3): 802 - 812. [Abstract] [Full Text] [PDF] |
||||
|
|